Protocol Ledger

Academic / Institutional Sponsor · Consolidated Sponsor Hub

Gruppo Oncologico del Nord-Ovest: Clinical Trials & FDA Approval Profile

Gruppo Oncologico del Nord-Ovest (Global / Institutional) sponsors 26 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 16 active protocols (9 recruiting now), 5 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)7.7%
Median Closed Enrollment vs National (145 pts)82 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Gruppo Oncologico del Nord-Ovest
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)26
Active Pipeline (Recruiting Now)16 (9)
Completed vs Stopped Early5 / 2 (7.7%)
Median Closed Actual Enrollment82 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Gruppo Oncologico del Nord-Ovest
Hospital Research SiteLocationShared Protocols
Azienda Ospedaliero Universitaria PisanaPisa5
Ospedale San RaffaeleMilan3

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Gruppo Oncologico del Nord-Ovest
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT06897644Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With APhase IIIRECRUITING
NCT06733038FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients.Phase IIIRECRUITING
NCT07407465Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer.Phase IIRECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the Gruppo Oncologico del Nord-Ovest Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI